ARTICLE | Clinical News
TD-6450: Phase IIa started
July 18, 2016 7:00 AM UTC
Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir ( BI 201335) with and without ribavirin for 12 weeks in 25 patients. Tre...